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Abstract: Heparin modulates function of vascular endothelium. We studied the effects of unfractionated 
heparin (UFH) vs. enoxaparin vs. sulodexide on the levels and gene expression of osteoprotegerin (OPG), 
Receptor Activator of Nuclear Factor kB Ligand (RANKL) and von Willebrand factor (vWF) in Human 
Umbilical Vein Endothelial Cells (HUVEC) culture. HUVEC were isolated from human umbilical vein 
by a standard method. The supernatant concentrations (ELISA) and gene expression (Real Time-PCR) of 
OPG, RANKL and vWF in HUVEC were determined after incubation with various concentrations of UFH, 
enoxaparin and sulodexide for up to 16 hours. In control HUVEC strong positive correlation between OPG 
and vWF levels was observed, whereas sRANKL negatively correlated with OPG and vWF levels. Only 
in control HUVEC a negative correlation between the supernatant level of vWF and its gene expression 
was found. Already the lowest concentration of UFH caused 2.5-fold increase in OPG gene expression 
while higher UFH concentrations substantially increased RANKL mRNA level. A negative correlation 
between the OPG and sRANKL concentration was noticed in supernatant HUVEC which were incubated 
with enoxaparine. In conclusion, the observed interrelationships between OPG, RANKL and vWF levels 
in unstimulated HUVEC support the presumption of the pathophysiological links between these proteins. 
Of the tested heparin formulas UFH seems to be the most potent in altering the OPG, RANKL and vWF 
axis. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 2, 156–163)
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Introduction
Heparins are widely used in the prevention of throm-
boembolic disease, in patients undergoing surgical, 
gynecological or orthopedic procedures, in hemo-
dialysis patients, and in many other clinical situations. 
Considering their all-systemic actions, effects of hepa-
rins on endothelial cells still remain unclear. Another 
drug with anticoagulant properties is sulodexide. 
Sulodexide presents as a heparin derivative (hepa-
rinoid), being a purified medium-molecular-weight 
glycosaminoglycan containing 80% of heparin sulfate 
and 20% of dermatan sulfate. Its anticoagulant action, 
like that of low-molecular-weight heparins (LMWHs), 
involves mainly the inhibition of the active factor X. 
Sulodexide has a smaller effect on thrombin (IIa), 
which helps to avoid hemorrhagic effects during its 
administration. 
Osteoprotegerin (OPG) is a tumor necrosis factor 
(TNF) family glycoprotein [1]. OPG is part of the 
axis of OPG/Receptor Activator of Nuclear Factor 
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kB (RANK)/Receptor Activator of Nuclear Factor 
kB Ligand (RANKL). RANKL, binding to its recep-
tor (RANK) expressed on the surface of target cells, 
triggers a cascade of intercellular signals that activate 
transcription factors (e.g. NFkb, N-terminal c-Jun 
kinase pathway) responsible for the maturation of 
osteoclasts. OPG competes with RANKL, blocking 
its binding to RANK, and thus inhibits osteoclasto-
genesis and counteracts bone mass loss [1]. 
The von Willebrand factor (vWF) is synthesized by 
endothelial cells and megakaryocytes, and then re-
leased to blood in the form of multimers. Its role in 
the process of hemostasis is to ensure proper platelet 
adhesion to injured sites in vascular endothelium and 
to protect factor VIII from its proteolytic degradation. 
The elevated level of vWF correlates with the degree 
of endothelial damage and constitutes a risk factor 
for thrombosis [2]. 
OPG is physiologically associated with vWF in Weibel
-Palade bodies of endothelial cells [3]. Heparins are 
known to exert well-documented effects on the release 
of vWF [4] and OPG [5] in vivo. To date, however, it 
has been unclear whether these effects are associated 
with each other. 
The study objective was to compare the effect of 
chosen heparins (UFH, unfractionated heparin, as 
well as LMWH, enoxaparin) and sulodexide on the 
concentrations and gene expression of OPG, RANKL 
and vWF in the cultures of endothelial cells of the 
human umbilical vein (HUVECs). 
Material and methods 
HUVEC culture. Endothelial cells of the human umbilical 
vein were used as material for the study. The umbilical 
cord was provided immediately after delivery of a healthy 
full-term newborn from normal pregnancy. The study was 
performed in conformity with Helsinki Declaration and local 
Ethics Committee approval was obtained. Cell isolation 
and arrangement of HUVEC culture followed standard 
procedures according to Jaffe [6, 7]. The umbilical vein 
was cannulated and perfused with HBSS solution (without 
Ca++ and Mg++) to remove blood and clots. Next, incubation 
was performed in a heated bath at 37°C for 10 min. Cell su-
spension was centrifuged and then the sediment containing 
HUVEC was placed in culture bottles (surface area of 75 cm3) 
coated with fibronectin (Nagle Nunc Intl. Inc., Penfield, 
NY, USA). We used M199 medium (SigmaAldrich Co., St. 
Louis, Missouri, USA) supplemented with 20% fetal calf 
serum, streptomycin 100 µg/mL, amphotericin B 0.25 µg/mL, 
penicillin G 100 IU/mL, ECGF 200 µg/mL (all purchased 
from SigmaAldrich). The cells were incubated in an at-
mosphere enriched with 5% CO2 (95% air). The primary 
culture was obtained at 90% confluence by visual assess-
ment, accounting for approximately 6 million cells counted 
in trypsinized cell suspension in a Bürker chamber. Next, 
the culture was passaged according to standard procedures 
(Figures 1, 2), by washing the cells with serum-free M199 
medium and trypsinization with 0.1% trypsin solution. The 
reported experiment was conducted at the third passage. 
For experimental purposes, the cells were sieved onto 24-pit 
culture plates (Nagle Nunc). In order to identify HUVECs, 
the culture was labeled with monoclonal antibodies against 
von Willebrand factor (Dako, Glostrup, Denmark). The 
medium used in the experiment contained neither heparin 
nor any other anticoagulant. 
Study design. All HUVECs used for the study were obtained 
from the same umbilical vein. Doses and timing of drug 
administration were calculated according to their phar-
macokinetic properties. The cells were cultured in 24-well 
Figure 1. HUVEC (Human Umbilical Vein Endothelial 
Cells) colony; first day after passage. Original magnifica-
tion × 100
Figure 2. HUVEC colony; fifth day after passage (full 
confluence); × 100
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culture plates (approximately 2.5 x 105 cells). The cultures 
were supplemented with unfractionated heparin at various 
concentrations (4, 20 and 40 µg/mL) for 1, 2 and 6 hours, 
and with enoxaparin (10, 50, 100 µg/mL) for 4, 8 and 16 ho-
urs. Additionally, sulodexide was applied at concentrations 
of 0.1, 0.5 and 1 µg/mL for 2, 4 and 6 hours of incubation. 
Unstimulated cultures were used as controls. Supernatant 
was obtained by pipetting it gently off HUVECs, and placing 
in Eppendorf tubes. 
Measurement of OPG, sRANKL and vWF secretion by 
HUVEC (ELISA). Supernatant concentrations of OPG 
(RayBiotech, Norcross, GA, USA), soluble (s)RANKL 
(Biomedica Group, Vienna, Austria) and vWF (Abnova, 
Taipei City, Taiwan) were determined by immunoenzymatic 
assays (ELISA) following the manufacturers’ instructions. 
Isolation of HUVEC RNA. Buffer RLT plus (350 µl) con-
taining b-mercaptoethanol was added to HUVEC (10 µl 
ME per 1 ml of buffer RLT) (SigmaAldrich). Next, the 
cells were ‘scratched’ using a pipette tip and transferred 
to a QIAshredder column (QIAGEN, Hilden, Germany). 
A QIAshredder kit was used for homogenization performed 
during centrifugation of the suspension for 2 min at the 
maximum speed. Subsequently, HUVEC RNA was isolated 
according to the producer’s instructions (RNAeasy Plus Mini 
Kit, QIAGEN, Hilden, Germany ). 
Measurement of OPG, RANKL and vWF mRNA levels in 
HUVEC by Real Time PCR. All the reagents used at this 
stage of the experiment were purchased from Applied 
Biosystems (Foster City, CA, USA). High capacity RNA-to
-cDNA kit was applied to induce the reverse transcription 
process in the obtained RNA. Real Time PCR was perfor-
med to assess the expression of the genes examined, using 
cDNA and oligonucleotide starters specific for the OPG, 
RANKL, vWF and 18S RNA genes as a matrix (Table 1). 
For these reactions we used a TaqMan Gene Expression 
Assay kit. As a reference system, TaqMan Ribosomal RNA 
Control Reagents kit was employed to amplify 18S rRNA 
gene. The PCR was started with an incubation at 95°C for 
10 min (30 cycles for 30 sec at 95°C), followed by incubation 
at 55°C for 30 sec (binding temperature). Binding of the 
polymerase and synthesis of the complementary strand to 
the matrix took place at 72°C for 30 sec, whereas termination 
of the reaction lasted for 10 min at 4°C. 
The 2-ΔCT values were used to analyze the correlations of 
OPG, RANKL and vWF gene expression. In real time PCR, 
the CT (threshold cycle) values were calculated for OPG, 
RANKL, vWF and ribosomal RNA (reference gene; 18S 
rRNA) as the mean from three CT measurements. Livak’s 
comparative method was applied to determine the relative 
level of gene expression (8) in relation to the reference gene 
(18S rRNA). The normalized value of the relative gene 
expression in an unknown sample in regard to the calibrator 
was calculated according to the formula: Fold Change (R) = 
= 2-ΔΔCT. The results so obtained are expressed as calibration 
(control) sample multiple. When the R parameter equals 
1, the expression levels or the number of gene copies in the 
calibration and unknown samples are identical. For gene 
expression (PCR) analysis the mRNA level of studied ge-
nes was defined in control cells as 1. The value lower than 
1 indicates higher gene expression in the calibration sample, 
whereas higher than 1 suggests higher gene expression in 
the unknown sample [8, 9].
Statistical analysis. The results of this preliminary study 
represent data obtained from two sets of cell incubations. 
Shapiro-Wilk’s W test of normality was used for data 
distribution analysis. The Spearman’s rank correlation 
coefficient was determined for all variables. Differences 
at p < 0.05 were considered statistically significant. Sta-
tistica program v. 10.0 (StatSoft, Cracow, Poland) was 
used for calculations. 
Results
Concentrations (ELISA) and gene expression (PCR) 
of OPG, RANKL and vWF in control HUVEC
In control HUVECs, the levels (ELISA) of OPG 
and vWF in cell supernatant increased with the 
experiment’s duration (Figures 3A, C) whereas the 
concentration of sRANKL, decreased during the 
course of incubation (mainly after 6 and 8 hours) 
(Figure 3B).
A number of correlations related mainly to protein 
concentrations was observed in the unstimulated cel-
ls. A strong positive correlation was found between 
the concentrations of OPG and vWF (R = 0.966, 
p < 0.001) in HUVEC supernatant. Simultaneously, 
negative correlations between the levels of OPG 
and sRANKL (R = –0.750, p = 0.019) and between 
sRANKL and vWF, (R = –0.850, p = 0.003) were 
observed. Interestingly, in control HUVECs a ne-
gative correlation between the level of vWF and its 
gene expression was found (R = –0.783, p = 0.012). 
Table 1. Trade names of the TaqMan kits used
Gene  Gene Expression TaqMan 
Assay Kit
OPG – TNFRSF11B Hs00900358_m1 (FAM)
RANKL – TNFSF11 Hs00243522_m1 (FAM)
vWF - VWF Hs00169795_m1 (FAM)
18S rRNA Hs03928985_g1 (FAM)
Abbreviation: FAM — 6-carboxyfluorescein-labeled probe
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The effect of unfractionated heparin on  
the concentration (ELISA) and gene expression 
(qPCR) of OPG, RANKL and vWF in HUVEC
The lowest concentration of UFH (4 µg/mL), compared 
with the control, caused a gradual and the most substan-
tial increase in the supernatant OPG levels, which was 
also observed with less intensity for the concentration 
of 20 µg/mL (Figure 3A). The incubation of HUVEC 
in the presence of UFH (especially at the lowest dose) 
decreased sRANKL concentration (Figure 3B). With 
the experiment duration, a trend was observed towards 
a gradual increase in vWF concentration, being most 
distinct at the highest UFH dose (Figure 3C). 
Unfractionated heparin caused a 2.5-fold increase in 
OPG gene expression as compared with the control, but 
only at the lowest dose and shortest time of incubation 
(Table 2A). However, in the remaining cases, UFH 
caused a decline in the expression of the OPG gene . In 
the case of RANKL mRNA, a substantial increase (even 
1433-fold) was noted for each UFH dose and incubation 
time. At the same time the gene expression of vWF sho-
wed a trend towards a substantial decrease (Table 2A).
During incubation of HUVECs with UFH, no signi-
ficant correlations were found either between the 
concentrations of the proteins studied or between the 
expression levels of their genes. 
The effect of enoxaparin on the concentration  
(ELISA) and expression (qPCR) of OPG,  
RANKL and vWF in HUVEC
HUVEC incubation with enoxaparin was associated 
with an increase in the level of OPG in supernatant as 
compared with the control, which was most distinctive 
after 16 hours of incubation at all concentrations used 
(Figure 4A). The highest dose of enoxaparin induced 
the greatest increase in the level of sRANKL after the 
first stage of incubation which gradually decreased in 
the subsequent hours of the experiment (Figure 4B). 
Lower doses of enoxaparin did not change sRNAKL 
supernatant levels as compared with control cells. The 
concentration of vWF after incubation of HUVECs 
with enoxaparin increased with time (Figure 4C). 
Enoxaparin at the concentration of 50 and 100 µg/mL 
increased vWF level in HUVEC supernatant after 4 
and 8 hours of incubation, however, at the later stages 
of incubation vWF levels prominently decreased after 
incubation with enoxaparin at the dose of 100 µg/mL 
(Figure 4C). Enoxaparin caused a falling trend in OPG 
gene expression (Table 2B). RANKL gene expression 
showed a substantial increase after the lowest dose of 
enoxaparin and the shortest incubation period (a 301-
fold increase as compared with the control). In the 
other cases, RANKL expression was found to rise only 
Figure 3. Concentration of OPG (A), sRANKL (B) and 
vWF (C) in the supernatants of control HUVECs and in 
cells incubated with various concentrations of unfractio-
nated heparin (UFH). Control — HUVECs incubated 
without heparins, OPG — Osteoprotegerin, sRANKL — 
soluble Receptor Activator of Nuclear Factor kB Ligand, 
vWF — von Willebrand Factor, h — hour
slightly or even decrease (Table 2). The expression of 
the vWF gene increased at small drug concentration 
and decreased at the higher ones (Table 2B). 
Under the enoxaparin usage we observed 
a negative correlation between the concentration 
of OPG and sRANKL in HUVEC culture supernatant 
(R = –0.733, p = 0.024).
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Figure 4. Concentration of OPG (A), sRANKL (B) and vWF 
(C) in the supernatants of control HUVECs and in cells 
incubated with various concentrations of enoxaparin. Control 
— HUVECs incubated without heparins, OPG — Osteopro-
tegerin, sRANKL — soluble Receptor Activator of Nuclear 
Factor kB Ligand, vWF — von Willebrand Factor, h — hour
The effect of sulodexide on the concentration  
(ELISA) and gene expression (qPCR) of OPG, 
RANKL and vWF in HUVEC
Under sulodexide supplementation we did not ob-
serve any relevant changes in the OPG, sRANKL 
and vWF concentrations in HUVEC supernatant 
compared with the control (Figure 5). Sulodexide cau-
sed a decrease in the OPG gene expression, although 
a slight increase was noted when HUVECs were 
incubated for 4 hours at its 0.5 µg/mL concentration 
(Table 2C). The expression of the gene encoding 
RANKL remained lower than control levels during 
incubation of the cells with sulodexide. Only the 
0.5 µg/mL concentration caused a 14-fold increase in 
RANKL gene expression after incubation for 2 hours 
(Table 2C). Sulodexide, like the other drugs, reduced 
vWF gene expression in HUVECs, although slight 
increase was once noted at a low dose of the drug.
During incubations of HUVECs with sulodexide, no 
statistically significant correlations were noted either 
between the proteins concentrations or between their 
genes’ expressions. 
Discussion
The current study presents the effects of different 
heparins and sulodexide on the relations between the 
OPG/RANKL system and vWF in vitro. Control HU-
VEC cultures showed an increase in the concentration 
of osteoprotegerin with incubation time. Simultaneo-
usly, strong negative correlation were noted between 
OPG and sRANKL as well as positive one between 
OPG and vWF levels in HUVEC supernatants. 
Numerous animal studies provided evidence 
for the protective role of OPG towards the arterial 
walls. OPG knockout mice showed calcification of 
the middle layer of the aorta and renal vessels, but 
not of smaller vessels [10]. However, data on a direct 
relationship between the level of OPG and stage of 
atherosclerosis in humans remain in opposition to 
those describing animal models. Prognostic signifi-
cance of the elevated concentration of serum OPG 
as the risk factor of fatal cardiovascular events was 
described in disorders associated with atherosclerosis, 
e.g. in elderly women [11], hemodialysis patients [12], 
or diabetic patients [13]. During these states increased 
release of OPG can be caused by endothelial damage, 
internal membrane smooth muscle cell proliferation 
as well as advanced calcification of atheroma. If we 
assume a protective role of this protein, its increase 
in the blood in cardiovascular diseases may indicate 
failure of the compensatory mechanisms. 
It has been suggested that the differences be-
tween UFH and LMWH in their effect on the OPG/ 
/RANKL system may play a role in the development 
of atherosclerosis. A study conducted in vivo by Vik 
et al. [14] presented the effect of UFH and LMWH 
(dalteparin) on plasma OPG concentration. Subcuta-
neous administration of high doses of dalteparin and 
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Table 2. Values of fold change of the mRNA levels of OPG, RANKL and vWF genes during the incubation of HUVECs 
with unfractionated heparin (UFH), enoxaparin and sulodexide 
A UFH (2-∆∆CT) B Enoxaparin (2-∆∆CT)
Con. Time OPG RANKL vWF Con. Time OPG RANKL vWF
4 µg/mL 1 h 2.45 1433.57 0.0058 10 µg/mL 4 h 0.31 301.92 0.00067
4 µg/mL 2 h 0.76 611.29 0.002 10 µg/mL 8 h 0.36 0.51 13.607
4 µg/mL 6 h 0.30 192.16 0.025 10 µg/mL 16 h 1.77 1.59 24.75
20 µg/mL 1 h 0.57 354.7 0.0019 50 µg/mL 4 h 0.99 2.47 0.40
20 µg/mL 2 h 0.87 1070.96 0.0056 50 µg/mL 8 h 2.38 4.31 13.50
20 µg/mL 6 h 0.40 135.23 0.046 50 µg/mL 16 h 0.28 0.427 0.649
40 µg/mL 1 h 0.82 344.94 0.0022 100 µg/mL 4 h 0.48 3.20 0.027
40 µg/mL 2 h 0.10 12.47 4.24E-05 100 µg/mL 8 h 0.38 1.31 0.49
40 µg/mL 6 h 0.26 372.82 0.0026 100 µg/mL 16 h 1.28 0.84 0.70
C Sulodexide (2-∆∆CT) Control definite as 1
Con. Time OPG RANKL vWF
0.1 µg/mL 2 h 0.18 0.736 0.72
0.1 µg/mL 4 h 1.13 2.74 0.34
0.1 µg/mL 6 h 0.189 0.95 1.49
0.5 µg/mL 2 h 1.71 14.02 0.55
0.5 µg/mL 4 h 0.70 0.88 0.156
0.5 µg/mL 6 h 0.158 0.47 0.086
1 µg/mL 2 h 0.76 0.472 0.008
1 µg/mL 4 h 0.685 0.608 0.035
1 µg/mL 6 h 0.355 0.48 0.039
Abbreviation: Fold Change = 2-∆∆CT ; ΔΔCT = ΔCT (unknown sample) — ΔCT (calibrator); Control — HUVEC without drugs; Con. — Concen-
tration; OPG, sRANKL, vWF as described for Figure 3
intravenous application of low doses of UFH were 
found to increase plasma OPG level in a similar way. 
However, UFH showed higher affinity to OPG than 
dalteparin [14]. Most recent observations referred to 
the intravenous use of both heparins [15], revealed 
no statistically significant differences between UFH 
or LMWH (fraxiparine) in increased OPG release. 
However, the use of fraxiparine was associated with 
lower increase of OPG plasma level during the first 
15 minutes of hemodialysis procedure [15]. We are not 
aware of any reports regarding the effect of heparins 
on OPG release in vitro.
In our study, the control HUVECs may be re-
garded as an example of the physiological release of 
the studied proteins in response to mechanical cell 
damage associated with cell culture technique. We 
demonstrated a strongly positive correlation between 
the concentrations of OPG and vWF in HUVEC con-
trol. The vWF is physiologically related to OPG by its 
A1 domain . The vWF-OPG complexes originate only 
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correlation) confirms this physiological relationship. 
Heparins, by activating the endothelium, release OPG 
and vWF from storage vesicles in HUVECs culture. 
In control HUVEC we also found negative corre-
lations between sRANKL and OPG concentration, 
as well as between sRANKL and vWF levels, which 
confirms the physiological axis of these proteins. One 
of the hypotheses suggests the relationship between 
changes in the levels of OPG and RANKL in the 
course of cardiovascular diseases. The association 
involves an incomplete compensatory mechanism, 
which at once presents a question referring to the 
involvement of RANKL and its receptors in the 
calcification of atheromas. It has been assumed that 
the ‘proinflammatory’ profile of cytokines observed in 
atherosclerosis increases the RANKL/OPG ratio and 
in this way causes accumulation of calcium deposits 
[17]. Our in vitro findings seem to confirm numerous 
reports on the presence of inverse relationship be-
tween the concentration of OPG and RANKL also 
in vessels that are free of calcification [18]. 
In our study, control endothelial cells showed 
a strong negative correlation between the concen-
tration of vWF and sRANKL. It is likely that the 
relationship between vWF and sRANKL is similar 
to that observed in the case of OPG and sRANKL. 
We also observed a negative correlation between 
the expression of the vWF gene in cells and its con-
centration in control HUVEC supernatant. The 
cells showed a rapid release of vWF and its gradually 
increasing expression reaching the peak during the 
final stage of the experiment. This is consistent with 
previous reports on a spontaneous release of vWF by 
HUVEC from Weibel-Palade bodies via exocytosis 
[19]. Galbusera et al. demonstrated an association 
between the increase in vWF concentration in HU-
VEC supernatant and shear stress of blood flow [19]. 
However, also in the control, the level of vWF was found 
to increase with incubation time. No difference was 
observed in the expression of the gene encoding vWF 
between control and drugs stimulated culture [19]. We 
observed a negative correlation between the expression 
of vWF and its concentration in the supernatant, but only 
in the control HUVECs. Incubation with UFH decre-
ased vWF expression, which could be related to partial 
HUVEC exhaustion under strong UFH stimulation. 
In our study, enoxaparin in the lowest concentra-
tion, impaired the release and expression of OPG, 
RANKL and vWF as compared with control cells 
and other tested drugs. It was the only drug which 
did not changed a negative correlation between the 
concentration of OPG and sRANKL, observed in 
control cells. This observation remains consistent 
with reports on the protective effect of low molecular 
Figure 5. Concentration of OPG (A), sRANKL (B) and 
vWF (C) in the supernatants of control HUVECs and in 
cells incubated with various concentrations of sulodexide. 
Control — HUVECs incubated without heparins, OPG — 
Osteoprotegerin, sRANKL — soluble Receptor Activator 
of Nuclear Factor kB Ligand, vWF — von Willebrand 
Factor, h — hour
via intracellular formation, and the reaction requires 
high level of calcium ions, low level of chlorine ions 
and pH 6.5. OPG and vWF are probably formed in 
the Golgi apparatus and stored as complexes in We-
ibel-Palade bodies [16]. The observed simultaneous 
release of OPG and vWF by control cells (positive 
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weight heparin on vascular endothelium, and on less 
pronounced extra-anticoagulation effects in patients 
treated with the LMWH [20, 21]. 
We found no correlations between the gene expres-
sion in HUVEC and proteins concentration in the 
supernatant when the cells were incubated with UFH. 
Thus, it seems that UFH had the strongest effects on 
the OPG, sRANKL and vWF axis. Heparins reduced 
sRANKL concentration in the supernatant. The level of 
RANKL expression remains low in healthy vessels, yet, 
it is much higher at the site of rupture of coronary blood 
clot [22]. However, our in vitro experiments show that 
the expression of the RANKL gene was markedly eleva-
ted during incubation of HUVECs with unfractionated 
heparin, and much less increased when enoxaparin was 
used. Thus, it is likely that prolonged incubation with 
UFH may increase the level of sRANKL in cell super-
natant due to the increased expression of RANKL gene. 
In conclusion, the observed relationships between 
OPG, RANKL and vWF levels and gene expression, 
affirmed mainly in control, unstimulated HUVECs, 
reinforces the presumption of the pathophysiologi-
cal linkage between these proteins. UFH occurred 
to be the most potent heparin which disturbs OPG/ 
/RANKL/vWF axis. Our findings help to understand, 
but surely do not fully explain, the influence of anti-
coagulant drugs on the endothelial cells in vitro.
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